03 July 2023
03 July 2023
The test is already commercialised in Europe and several international markets.
BCAL scientists leveraged SydneyMS’ technology to discover novel lipid biomarkers for breast cancer.
New data shows promising results for ArteraAI’s AI-derived biomarker for predicting androgen deprivation therapy for those susceptible to prostate cancer.
ProFound AI 3.0 is a third-generation artificial intelligence for digital breast cancer detection.
The laboratory already performed its first commercial test by examining a patient sample for fetal Rhesus D blood group status.
Cresilon’s haemostatic gel, already cleared for use in veterinary medicine, has now received 510(k) clearance for human use.
By leveraging FEops HEARTguide, physicians can eliminate the use of manual measurements.
The antibody detection kit is intended as a companion to Roctavian gene therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
